German Merck Identifies Pipeline Stars, Plots Course Through A Dynamic Cancer Space
Executive Summary
As questions remain over Merck KGAA's ability to retain its top line following the patent loss for its key products Rebif and Erbitux, the German company has highlighted some of its higher priority R&D programs in its "very interesting" pipeline, as well as its strategy to make the most of the assets.
You may also be interested in...
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Merck KGaA To Exit Biosimilars? That Would Be No Surprise To Analysts
Germany's Merck KGaA is reportedly making soundings to sell its biosimilar business to focus on its expanding pipeline.
Interview: German Merck Set For Big "Leap" In India
Germany's Merck Group appears set to build on its strong showing in India. Belén Garijo, CEO of Healthcare at Merck KGAA, tells Scrip about efforts to "consumerize" the firm's primary care business, how Erbitux is the "backbone" on which the company will build its oncology presence, and plans to roll out new products including the clinical stage immune-oncology asset avelumab, in India.